Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Torii Pharmaceutical Co Ltd
4551Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. In addition, it is engaged in real estate rental business. The company markets its products primarily through medical representatives for medical professionals. The company has a collaboaration with ALK-Abelló A/S to develop, market and distribute ALK's allergy immunotherapy tablet for the treatment of grass pollen allergy. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc. Address: Torii Nihonbashi Bldg., Tokyo, Japan, 103-8439
Analytics
Objectif de Cours de WallStreet
622 741.89 JPYRatio C/B
24.0543Rendement du dividende
2.84 %Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés 4551
Analyse des dividendes 4551
Croissance des dividendes sur 5 ans
150 %Croissance continue
2 annéesRatio de distribution Moyenne sur 5 ans
49 %Historique des dividendes 4551
Valorisation des titres 4551
financières 4551
Résultats | 2019 | Dynamique |